Heartland Advisors Inc. lifted its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 12.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 100,257 shares of the medical instruments supplier’s stock after acquiring an additional 11,089 shares during the quarter. Becton, Dickinson and Company makes up approximately 1.0% of Heartland Advisors Inc.’s investment portfolio, making the stock its 14th largest position. Heartland Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $19,457,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of BDX. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. Empowered Funds LLC grew its holdings in Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after purchasing an additional 1,354 shares during the period. United Bank grew its holdings in Becton, Dickinson and Company by 23.9% during the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after purchasing an additional 993 shares during the period. Marshall Wace LLP grew its holdings in Becton, Dickinson and Company by 365.1% during the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after purchasing an additional 25,022 shares during the period. Finally, NewEdge Advisors LLC grew its holdings in Becton, Dickinson and Company by 34.7% during the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after purchasing an additional 6,058 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.
Becton, Dickinson and Company Trading Down 2.6%
Shares of NYSE:BDX opened at $148.14 on Thursday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The stock has a market cap of $40.82 billion, a PE ratio of 37.50, a P/E/G ratio of 10.76 and a beta of 0.22. The business has a 50 day moving average of $150.40 and a 200-day moving average of $174.56. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.
Becton, Dickinson and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is currently 106.33%.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on BDX shares. Evercore lifted their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Barclays lifted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Piper Sandler reduced their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Weiss Ratings cut Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Finally, Argus reduced their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a report on Monday, March 23rd. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and a consensus price target of $183.64.
View Our Latest Stock Report on BDX
Insider Activity
In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,913 shares of company stock worth $426,806 in the last three months. Insiders own 0.40% of the company’s stock.
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
